GSK plots £400m Cambridge research hub in push for cancer breakthroughThe telegraph·Jul 28 at 09:11 AMNUVL0.00%GSK+151.00%
Citigroup Reiterates "Neutral" Rating for GSK (NYSE:GSK)Market Beat·Jul 24 at 07:06 AMGSK+151.00%NUVL0.00%
Jideytro (zidesamtinib) approved in the US for previously treated ROS1-positive non-small cell lung cancer | GSK Stock NewsStockTitan·Jul 22 at 04:58 AMGSK+151.00%GSK
Nuvalent, Inc. (NASDAQ:NUVL) Receives Consensus Rating of "Hold" from AnalystsMarket Beat·Jul 20 at 01:14 AMNUVL0.00%BAC+27.00%
Nuvalent seeks Nasdaq delisting, plans to end SEC reporting after merger closesPUBT·Jul 15 at 08:04 AMNUVL0.00%
GSK Pays $10.6 Billion for Nuvalent to Accelerate Lung Cancer PushTip Ranks·Jul 15 at 07:42 AMNUVL0.00%GSK
REG - GSK PLC - GSK completes acquisition of Nuvalent, IncLondon Stock Exchange·Jul 15 at 07:38 AMNUVL0.00%GSK+151.00%
Nuvalent CEO James Richard Porter disposes of 30,000 common shares for $3.71 millionPUBT·Jul 8 at 03:31 PMNUVL0.00%
